Adma Biologics, Inc. Announces That Dov A. Goldstein Will Not Stand for Reelection as A Member of the Board
April 28, 2020 at 05:07 pm EDT
Share
On April 27, 2020, Dov A. Goldstein, M.D. notified the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) that he will not stand for reelection as a member of the Board at the next annual meeting of stockholders. Dr. Goldstein served as a member of the Company’s Board since 2007 and also served as Chairman of the Board’s Compensation Committee. Dr. Goldstein’s decision not to stand for reelection was not due to any disagreements with the Company on any matter relating to the Company’s operations, policies, or practices.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
ADMA BIOLOGICS, INC. 
